August 10, 2010Open Access

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Key Points

Key points are not available for this paper at this time.

Abstract

These results confirm that IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Perez et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69da4fde84371aa676a3d12e — DOI: https://doi.org/10.1200/jco.2009.26.2154

Authors

Edith A. Perez

Monica M. Reinholz

David W. Hillman

Journals

Journal of Clinical Oncology

Actions

Institutions

Indiana University – Purdue University Indianapolis

Mayo Clinic in Florida

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion